<DOC>
	<DOCNO>NCT01667302</DOCNO>
	<brief_summary>The purpose study evaluate efficacy tolerability radiotherapy follow adjuvant chemotherapy stage I/II NK/T-cell lymphoma .</brief_summary>
	<brief_title>Radiotherapy Followed Adjuvant Chemotherapy NK/T-cell Lymphoma</brief_title>
	<detailed_description>For patient stage I/II NK/T-cell lymphoma , sequence radiotherapy chemotherapy controversial . Some study demonstrate advantage upfront radiotherapy . Therefore , design single-arm phase II study evaluate efficacy safety radiotherapy follow adjuvant chemotherapy DICE regimen plus peg-asparaginase proved effective NK/T-cell lymphoma .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , Extranodal NK-T-Cell</mesh_term>
	<criteria>Age range 1470 year old Histological confirm , previously untreated stage I/II NK/T cell lymphoma upperaerodigestive tract ECOG performance status 01 Life expectancy 3 month Without prior history pancreatitis Adequate bone marrow organ function Low risk population ( Definition : stage I without local invasion , B symptoms high LDH level ) Pregnant lactate woman With contraindication steroid include uncontrolled diabetes Serious uncontrolled disease intercurrent infection History malignancy except cure basal cell carcinoma skin carcinoma insitu uterine cervix</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>NK/T-cell lymphoma</keyword>
	<keyword>Radiotherapy</keyword>
	<keyword>Adjuvant chemotherapy</keyword>
</DOC>